Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 5 Uveal Melanoma 1 Skin Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Carcinoma, Merkel Cell 1 Burkitt Lymphoma 1

Interventions

pembrolizumab 24 Nivolumab 23 aldesleukin 21 Cyclophosphamide 20 Ipilimumab 17 Interleukin-2 17 fludarabine 15 fludarabine phosphate 14 cemiplimab 12 Radiotherapy 7 Fluorouracil 7 Biopsy 7 dabrafenib 6 Surveys and Questionnaires 6 Dacarbazine 6 trametinib 5 binimetinib 5 Vemurafenib 5 Temozolomide 5 Surgical Procedures, Operative 5 Sirolimus 5 Radiation 5 Blood Specimen Collection 5 Aminolevulinic Acid 5 sonidegib 4 encorafenib 4 Photochemotherapy 4 Mohs Surgery 4 HhAntag691 4 Educational Status 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Skin Neoplasms × oblimersen × Dermatologic × Clear all

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡